Research Article
Identification and Preclinical Pharmacology of the γ-Secretase Modulator BMS-869780

Jeremy H. Toyn,1 Lorin A. Thompson,2 Kimberley A. Lentz,3 Jere E. Meredith Jr.,1 Catherine R. Burton,1 Sethu Sankaranararyanan,1 Valerie Guss,1 Tracey Hall,1,4 Lawrence G. Iben,1 Carol M. Krause,1 Rudy Krause,1 Xu-Alan Lin,1 Maria Pierdomenico,1 Craig Polson,1 Alan S. Robertson,1 R. Rex Denton,3 James E. Grace,3 John Morrison,3 Joseph Raybon,3 Xiaoliang Zhuo,3 Kimberly Snow,3 Ramesh Padmanabha,5 Michele Agler,5,6 Kim Esposito,5 David Harden,5 Margaret Prack,5 Sam Varma,5,7 Victoria Wong,5,8 Yingjie Zhu,5,9 Tatyana Zvyaga,5 Samuel Gerritz,2 Lawrence R. Marcin,2 Mendi A. Higgins,2 Jianliang Shi,2 Cong Wei,10,11 Joseph L. Cantone,10 Dieter M. Drexler,10 John E. Macor,2 Richard E. Olson,2 Michael K. Ahljanian,1 and Charles F. Albright1

1 Exploratory Biology and Genomics, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, USA
2 Discovery Chemistry, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, USA
3 Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, USA
4 Preclinical Sciences, Alexion Pharmaceuticals, Inc 352 Knottor Drive, Cheshire, CT 06410, USA
5 Lead Discovery and Lead Profiling, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, USA
6 High Throughput Biology, Boehringer Ingelheim, 900 Ridgebury Road, Ridgefield, CT 06877, USA
7 Stratford High School, 45 North Parade, Stratford, CT 06615, USA
8 External Research Solutions, WWMC, Pfizer World Wide Research & Development, Eastern Point Road, Groton, CT 06340, USA
9 Arvinas Inc, 5 Science Park, New Haven, CT 06511, USA
10 Discovery Analytical Sciences, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, USA
11 Department of Pharmacokinetics, Dynamics and Metabolism, Pfizer World Wide Research & Development, Eastern Point Road, Groton, CT 06340, USA

Correspondence should be addressed to Jeremy H. Toyn; toynhouse@aol.com

Received 28 March 2014; Accepted 18 May 2014; Published 8 July 2014

Academic Editor: George Perry

Copyright © 2014 Jeremy H. Toyn et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Alzheimer’s disease is the most prevalent cause of dementia and is associated with accumulation of amyloid-β peptide (Aβ), particularly the 42-amino acid Aβ1-42, in the brain. Aβ1-42 levels can be decreased by γ-secretase modulators (GSM), which are small molecules that modulate γ-secretase, an enzyme essential for Aβ production. BMS-869780 is a potent GSM that decreased Aβ1-42 and Aβ1-40 and increased Aβ1-37 and Aβ1-38, without inhibiting overall levels of Aβ peptides or other APP processing intermediates. BMS-869780 also did not inhibit Notch processing by γ-secretase and lowered brain Aβ1-42 without evidence of Notch-related side effects in rats. Human pharmacokinetic (PK) parameters were predicted through allometric scaling of PK in rat, dog, and monkey and were combined with the rat pharmacodynamic (PD) parameters to predict the relationship between BMS-869780 dose, exposure and Aβ1-42 levels in human. Off-target and safety margins were then based on comparisons to the predicted exposure required for robust Aβ1-42 lowering. Because of insufficient safety predictions and the relatively high predicted human daily dose of 700 mg, further evaluation of BMS-869780 as a potential clinical candidate was discontinued. Nevertheless, BMS-869780 demonstrates the potential of the GSM approach for robust lowering of brain Aβ1-42 without Notch-related side effects.
1. Introduction

Alzheimer’s disease (AD) is the most prevalent cause of dementia. More than 35 million people have dementia worldwide and the prevalence is expected to double in the next 20 years [1]. Medicines are available for treatment of symptoms but provide limited benefit and do not prevent AD [2]. The cause of AD is not completely understood, but a widely held view of its pathogenesis is based on the amyloid hypothesis. Accumulation and aggregation of the toxic amyloid-β peptide (Aβ), particularly the 42-amino acid form Aβ1-42 [3], initiates neuronal dysfunction that eventually leads to brain atrophy, dementia, and death [4, 5]. Aβ is naturally produced in the brain by proteolytic processing of a type I transmembrane protein, the amyloid-β precursor protein (APP). APP is processed by the β-site APP cleaving enzyme (BACE), releasing a secreted ectodomain and a membrane-anchored C-terminal fragment (APP-CTFβ). Subsequent cleavage of APP-CTFβ within the transmembrane domain by γ-secretase then produces a cytosolic intracellular domain (AICD) and Aβ, which is secreted. In addition, a fraction of APP is cleaved by α-secretase at a site within the Aβ sequence to produce APP-CTFα, which is subsequently cleaved by γ-secretase to produce nonamyloidogenic peptides [6]. Compounds targeting either BACE or γ-secretase have been tested in clinical trials, but adequate Aβ-lowering at tolerated doses in patients has been a challenge [7].

γ-Secretase is a lipid bilayer-embedded aspartate protease consisting of four core subunits; nicastrin, Aph-1, Pen-2, and presenilin. Presenilin carries the active site aspartyl residues, whereas the other subunits play ancillary roles in enzymatic activity and maturation [6, 8, 9]. Structural studies of γ-secretase using electron micrographic image analysis and biochemical methods to map locations of amino acid residues suggest a compact structure with the active site contained within a hydrophilic chamber surrounded by transmembrane domains [10–14]. High resolution structure of γ-secretase has not been reported, but, based on analogy to X-ray crystallography of a presenilin homolog [15], it seems likely that the active site aspartates would be located within an intramembrane pore surrounded by the transmembrane domains of presenilin. The biological role of γ-secretase involves the proteolytic cleavage of transmembrane domains of at least 80 different protein substrates, including APP and the Notch family [16]. Although the physiological significance of substrate processing is unknown in most cases, γ-secretase cleavage of Notch and production of the Notch intracellular domain (NICD) are critical for adult cell differentiation in the immune system and gastrointestinal tract [17, 18]. Inhibitors of γ-secretase (GSI) can be effective for Aβ lowering; however Notch inhibition likely contributes to dose-limitation [19].

A class of small molecules that avoid Notch inhibition are the γ-secretase modulators (GSM), which, like GSIs, target presenilin [20–24]. In contrast to GSIs, which inhibit Aβ production, GSMs have relatively little overall effect on Aβ production. Instead, GSMs change the lengths of Aβ peptides produced, causing decreased amounts of longer peptides, such as Aβ1-40 and Aβ1-42, and increased amounts of shorter peptides, such as Aβ1-37 and Aβ1-38 [25]. GSMs have analogous effects on other γ-secretase substrates, including Notch, causing a shift from the longer Nβ1-25 to the shorter Nβ1-21 Notch-derived peptides [26, 27]. The shift from longer to shorter Aβ peptides was first described for several nonsteroidal anti-inflammatory drugs (NSAID), which have low potency GSM activity [28], and was subsequently found in other small molecules and natural products [25]. The effect of GSMs is thought to result from allosteric stimulation of the stepwise cleavage mechanism of γ-secretase. The stepwise mechanism initiates with an endopeptidic cleavage of APP-CTF near the cytosolic face of the lipid bilayer, at either position 48 or position 49 (using the conventional amino acid numbering starting at position 1 for the aspartyl residue at the N-terminus of Aβ). Subsequently, γ-secretase carries out a series of carboxypeptidase-like cleavages at three or four amino acid intervals thereby producing tripeptides or tetrapeptides and Aβ peptides of different lengths [29, 30]. Typically, the 40-amino acid long Aβ1-40 is the major product, but lesser amounts of other Aβ peptides such as Aβ1-38 and Aβ1-42 are also produced. For example, Aβ1-40 biogenesis appears to require four cycles of APP-CTF cleavage at positions 49, 46, 43, and 40, resulting in the release of three tripeptides and one AICD (amino acids 50–99) for each Aβ1-40 peptide produced. Likewise, production of the Aβ1-42 peptide is associated with a series of cleavages that start at position 48 of APP-CTF [30, 31]. In the presence of a GSM, γ-secretase carries out an increased number of carboxypeptidase-like cycles per molecule of APP-CTF substrate, resulting in shorter Aβ peptides without substantially affecting the overall amount of Aβ produced [27, 32].

Despite having low potency, NSAID GSMs such as flurbiprofen were reported to lower brain Aβ1-42 in rodents [33, 34]. However, in clinical trials, flurbiprofen (tarenflurbil) was found to have no effect on Aβ1-42 in cerebrospinal fluid even at high doses [35]. High potency GSMs have also entered early stage clinical trials, but effects on Aβ1-42 in cerebrospinal fluid have not been reported [36, 37]. Many further GSMs have been evaluated in vitro and in animal studies, which, like the NSAID GSMs, do not inhibit Notch or other γ-secretase substrates [25, 38–51]. In addition, chronic dosing of GSMs has been reported to ameliorate plaque pathology [39, 45, 52] and enhance cognition in APP transgenic mice [48, 52, 53]. Thus, GSMs are capable of lowering brain Aβ1-42 and are expected to avoid the dose limitations of GSIs that are due to Notch-related side effects. A number of studies have reported at least some of the systemic exposure data associated with brain Aβ1-42 lowering, thus giving an idea of active exposures and doses for GSM [39–42, 44–46, 52]. However, preclinical predictions relating to safety margins or human dose have not been reported. Furthermore, the active exposures and doses in rodents are high, making it a matter of conjecture whether or not any of the currently published GSMs are likely to exhibit adequate safety margins or clinically acceptable doses. Here we describe the pharmacological properties of the GSM BMS-869780, a potent bicyclic triazole GSM [54, 55], and the quantitative predictions of human dose and off-target side effects. While these outcomes prevented the development of BMS-869780, they put in perspective the
extent of further enhancements in drug-like properties that would be necessary to justify clinical testing of a future GSM.

2. Materials and Methods

2.1. Compounds. The GSM, BMS-869780 [54, 55], and the GSIs BMS-299897 [56] and BMS-433796 [57] have been reported previously. The GSI BMS-698861 is described in a BMS patent [58]. Chemical structures are shown in Figure 1(a).

2.2. Cell Cultures. H4-APPSw cell cultures were maintained on Dulbecco’s modified Eagle’s medium (DMEM) supplemented with L-glutamine (2 mM), fetal bovine serum (10%), and G418 (100 μg/mL). For IC50 determinations, cells were harvested, resuspended in DMEM supplemented with 0.0125% bovine serum albumin, and dispensed into 384-well plates (1.5 x 10^4 cells per well). Aβ1-42 and Aβ1-40 assays, and Notch inhibition assays, were carried out as described previously [59]. Mouse embryonic fibroblasts deficient in PS1 and PS2 (MEF dKO) [60] were passaged twice per week in DMEM/F-12 medium, consisting of

---

**Figure 1:** (a) Chemical structures of the compounds used in this study are shown. (b) Overview of the HTS and subsequent triage of compounds summarizes experimentation steps in boxes, with outcomes indicated beside the arrows. Costs of reagents and disposables were a major consideration in the design, particularly the initial screen of 10^6 samples. (c) Principle of the Aβ1-42 immunoassay; simultaneous binding of monoclonal antibody conjugates 252-APC and 565-Eu (specific for C-terminus of Aβ1-42) to Aβ1-42 leads to FRET-based emission at 665 nm. The ratio of emission at 665 nm to fluorescence at 615 nm represents the level of Aβ1-42 in the sample. (d) Principle of the Aβ1-40 immunoassay; same as described above for the Aβ1-42 immunoassay, except that the monoclonal antibody conjugate TSD-Eu (specific for C-terminus of Aβ1-40) was used in place of 565-Eu.
Figure 2: In vitro potency of BMS-869780 in the HTS assay. (a) H4-APPsw cultures were treated overnight with BMS-869780 (a GSM) at a range of concentrations and the relative levels of Aβ1-42 (red ⬤) and Aβ1-40 (blue ◆) were determined for calculation of IC₅₀ values (summarized in Table 1). (b) H4-APPsw cultures were treated overnight with BMS-299897 (a representative GSI) as described for BMS-869780 in panel (a). IC₅₀ values are summarized in Table 1. (c) IC₅₀ values for Aβ1-42 and Aβ1-40 lowering were determined for 236 GSM (red ⬤) and for 688 GSI that were mostly of the type containing the aryl sulfonamide core (blue ◆). For some compounds, the Aβ1-40 IC₅₀ value was greater than 30 μM, the highest concentration tested in the Aβ1-40 assay (arrow). (d) The ratio of the Aβ1-40 IC₅₀ to Aβ1-42 IC₅₀ was plotted against Aβ1-42 IC₅₀ for the same 236 GSM illustrated in (c).

2.3. Aβ Antibodies and Conjugates. Anti-Aβ monoclonal antibodies and their epitopes used in this study were 4G8 (Aβ17-24; Covance), 252Q6 (rodent Aβ1-12; Invitrogen), D2A6H (Aβ37 C-terminal; Cell Signaling, catalog number...
12356BF), TSD (A\(\beta\)40 C-terminal), 26D6 (human A\(\beta\)1-12), and 565 (A\(\beta\)42 C-terminal; Bristol-Myers Squibb). The covalent antibody-fluorophore conjugates were made at Perkin-Elmer, including TSD-Europium cryptate (TSD-Eu), 565-Europium cryptate (565-Eu), and 26D6-allophycocyanin (26D6-APC). Streptavidin-horseradish peroxidase (SA-HRP) and 4G8-biotin conjugates were from Covance. Horseradish peroxidase (HRP) conjugates of 565, 26D6 and 252Q6 (565-HRP, 26D6-HRP and 252Q6-HRP) were made using preactivated HRP (Easylink, Zymed/Invitrogen). The 6E10-sulfo-tag conjugate was from Mesoscale Discovery (catalog number K15148E-1), and the 252Q6-sulfo-tag conjugate was made using a kit (Mesoscale Discovery catalog number R91AN-1).

2.4. Immunoassays. IC\(_{50}\) determinations for A\(\beta\)1-42 and A\(\beta\)1-40 in H4-APP\textsubscript{sw} cultures in 384-well format were determined using homogeneous time-resolved fluorescence immunoassays as previously described [59]. The principle of these assays is illustrated in Figures 1(c) and 1(d). In other experiments using H4-APP\textsubscript{sw} cultures, A\(\beta\) was quantified by ELISA; for A\(\beta\)1-40 the of monoclonal antibodies was 26D6 and 565-HRP; for A\(\beta\)1-40 it was TSD and 26D6-HRP, and for A\(\beta\)1-x it was 4G8 and 26D6-HRP. In some experiments a novel 4-plex A\(\beta\) electrochemiluminescence immunoassay was used (Mesoscale Discovery catalog number N452ZA-1). Briefly, the 4-plex was carried out in 96-well format, with 4 separate spots of capture antibodies in each well. The 96-well plates were prepared by the manufacturer, with spots of monoclonal antibodies for A\(\beta\)1-42, A\(\beta\)1-40, and A\(\beta\)1-38, and an additional fourth spot of streptavidin in each well. Plates were initially incubated with blocking buffer (5% BSA in phosphate buffered saline, 200 \(\mu\)L per well) for 2 hours at ambient temperature and then with D2A6H-biotin conjugate (50 ng/mL in 1% BSA, phosphate buffered saline, 25 \(\mu\)L per well) for 1 hour. Plates were then rinsed with phosphate buffered saline before addition of experimental samples for determination of A\(\beta\)1-42, A\(\beta\)1-40, A\(\beta\)1-38, and A\(\beta\)1-37 levels, following the manufacturer's instructions as for the A\(\beta\) 3-plex kit (catalog number K15148E-1). Rat brain extracts for use in the 4-plex assay were made in 0.2% diethylamine, as previously described [62]. For detection of rat A\(\beta\) peptides in the 4-plex (Figure 5), 252Q6-sulfo-tag conjugate was used, and for detection of human A\(\beta\) peptides from cell cultures 6E10-sulfo-tag conjugate was used. For A\(\beta\) in transiently transfected PS1/PS2 dKO fibroblasts, A\(\beta\)1-42 was quantified using an ELISA kit (WACO), and A\(\beta\)1-40 was quantified by ELISA as described above for H4-APP\textsubscript{sw} cultures. For triple transgenic mice (3xTg; [63]), human transgenic A\(\beta\)1-42 was assayed in brain homogenates using an ELISA kit (WACO). For the rat and mouse experiments illustrated in Figures 7 and 8, brain samples were prepared by solid phase extraction [64], and endogenous rat brain A\(\beta\)1-42 and A\(\beta\)1-40 were quantified by ELISA as previously described for wild type mice [65]. For brain extracts made using solid phase extraction, calibration of A\(\beta\) was relative, based on the approximately linear response of the assay in the range tested. For brain extracts made in 0.2% diethylamine, A\(\beta\)1-42, A\(\beta\)1-40, A\(\beta\)1-38, and A\(\beta\)1-37 concentrations in brain and cell culture samples were determined by fitting the results of immunoassays against calibration curves derived from a range of dilutions of the corresponding synthetic peptides on each assay plate using a quadratic curve fit (Graphpad Prizm 5.0). A\(\beta\)1-x was calibrated in the same way against synthetic A\(\beta\)1-40 peptide. Results were expressed in units of pM, corrected for sample dilution.

2.5. Immunodepletion of A\(\beta\). For immunodepletion of rat brain A\(\beta\), solid phase extracts [64] were pooled within treatment groups. The pools were divided into equal aliquots and incubated with or without monoclonals 565, TSD, 4G8, or 6E10 (10 \(\mu\)g) at 4°C overnight. Protein G beads (50 \(\mu\)L; EZview, Sigma) were added, and incubation was continued with agitation for 1 hour. The beads were removed by centrifugation, and A\(\beta\)1-40 and A\(\beta\)1-42 in the unbound fraction were quantified by ELISA, as described above.

2.6. Western Blotting. For western blotting of A\(\beta\) peptides from H4-APP\textsubscript{sw} cell cultures, A\(\beta\) was immunoprecipitated directly from the cell culture medium and was eluted from the protein G beads by addition of lithium dodecyl sulfate (LDS) electrophoresis sample buffer (Invitrogen). A\(\beta\) peptides were separated by gel electrophoresis in the presence of 8M urea [66], transferred to PVDF membrane, and detected by western blotting using monoclonal 26D6-HRP conjugate. For western blotting of APP-CTF in cell lysates, H4-APP\textsubscript{sw} cell cultures in T-75 flasks were rinsed with DPBS, harvested, isolated by centrifugation, and stored at −80°C until needed. Cells were suspended in SDS sample buffer (20,000 cells/\(\mu\)L), boiled for 10 min, and centrifuged 3000 \(\times\) g for 5 min. Total protein content was determined using an assay kit (EZQ, Invitrogen cat number R33200). Proteins were separated by electrophoresis on Bis-Tris 16% polyacrylamide gels and transferred to nitrocellulose filters. APP-CTF was detected using 26D6-HRP, and APP-CTF\textsubscript{a} was detected using ct695 polyclonal (Invitrogen, cat number 51-2700) and secondary goat anti-rabbit horseradish peroxidase conjugate (Zymed, catalog number 62-6120). Chemiluminescence images were captured and quantified using an imaging station (Fuji model number LAS-3000). The ct695 western blots also show APP-CTF\textsubscript{b}, which migrates as a fainter band above APP-CTF\textsubscript{a} under these conditions. To confirm the consistency of sample loading, the APP-CTF western blots were reprobed for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) using monoclonal ID4 (Enzo Life Sciences, cat number CSA-335).

For immunoprecipitation and western blotting of APP-CTF\textsubscript{b} and APP-CTF\textsubscript{a} from rat brain, weighed sagittal brain halves were homogenized using a rotary homogenizer (Polytron) in 5 volumes of RIPA buffer (Sigma R-0278; 150 mM NaCl, 1.0% IGEPAL CA-630, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris, pH 8.0) containing protease inhibitors (Roche complete cat number I836145001) and centrifuged at 25,000 \(\times\) g for 30 min. All steps were carried out on ice or at 4°C. The pellet from centrifugation was
discarded. Total protein concentration in the supernatant was determined using BCA protein assay (Pierce number 23227), and all samples were adjusted to a concentration of 18 mg/mL by addition of RIPA buffer. For APP-CTFβ immunoprecipitation, 5 μg of 252Q6 was added to 1 mL of homogenate and incubated on ice for 1 hour, and then 50 μL of magnetic protein A/G beads (Thermo Scientific cat number 88803) was added, and incubation was continued overnight with mixing. Using a magnet to isolate the beads, beads were washed once with 1 mL RIPA and twice with 1 mL of Tris saline pH 7.5 (50 mM Tris PH 7.5, 15 mM NaCl). The beads were resuspended in 40 μL of SDS sample buffer, boiled 5 mins, and removed using the magnet before gel electrophoresis and western blotting using ct695 polyclonal, as described above. For APP-CTFγ, 5 μg of 4G8 was added to homogenates previously used for immunoprecipitation of APP-CTFβ, and immunoprecipitation using magnetic beads followed by western blotting using ct695 polyclonal was carried out as described above.

2.7. Mass Spectrometry of Aβ Peptides from Cell Cultures. H4-APPsw cell cultures were grown in T-75 flasks until 75% confluent and rinsed with Dulbecco’s phosphate buffered saline (DPBS; Gibco cat number 14109), and 20 mL of DMEM supplemented with L-glutamine (2 mM), genetin, penicillin, streptomycin, and DMSO with or without BMS-869780 supplemented with L-glutamine (2mM), geneticin, penicillin, streptomycin, and DMSO. Immediately after reaching 75% confluency, the 4G8 antibody (1 μg/mL) was added (final concentration of DMSO was 0.2%). After incubation for 24 hours at 37°C in 5% CO2, culture medium was removed, centrifuged to remove cells, and frozen in aliquots at -80°C. For immunoprecipitation, aliquots of cell medium (4 mL) were thawed, followed by the addition of protease inhibitor cocktail (Sigma P-8340) to a final concentration of 1%, 60 ng of [15N]-Aβ1-40 synthetic peptide (rPeptide, 1101-1, Athens, GA), 30 μg of monoclonal 2D6, and 15 μg of monoclonal 4G8. After incubation for 20 min on ice, 80 μL of protein G agarose beads (Pierce Rockford, IL) was added, and incubation was continued overnight at 4°C. Beads were isolated by centrifugation and washed three times by centrifugation in 1 mL of ice cold phosphate buffered saline and then washed a final time in 1 mL 10 mM Tris-HCl pH 8.0. Aβ was eluted from the beads using 30 μL of 70% acetonitrile/0.1% formic acid. MALDI-TOF MS analysis was conducted using a Bruker Ultraflex III TOF/TOF mass spectrometer (Billerica, MA). A mix of Aβ standard peptides (AnaSpec, Fremont, CA) Aβ1-37 ([M+H]+ = m/z 4071.5), Aβ1-38 ([M+H]+ = m/z 4128.5), Aβ1-39 ([M+H]+ = m/z 4227.7), Aβ1-40 ([M+H]+ = m/z 4326.9), Aβ1-42 ([M+H]+ = m/z 4511.2), and [15N]Aβ1-40 ([M+H]+ = m/z 4378.4) was prepared to a final concentration of 1 ng/μL in 50%:50% acetonitrile : water (v:v). Both the standard peptide sample and the samples from H4-APPsw cell medium following immunoprecipitation (IP) were further processed by mixing 5 μL sample with 5 μL of 7 mg/mL MALDI matrix (α-cyano-4-hydroxycinnamic acid, CHCA, from Sigma-Aldrich, St. Louis, MO) in 70%: 30% acetonitrile : water (v:v) with 0.1% trifluoroacetic acid (v:v). 0.5 μL of sample was spotted to an AnchorChip 384-Well target plate (Bruker Daltonics, Billerica, MA) and allowed to dry in air before analysis. Analysis of various Aβ peptide isoforms from the standard peptides and the cell samples was performed in positive linear mode, accumulating 2000 spectra. Intensities of each analyte were normalized against a MALDI matrix peak (m/z 824.8) and the internal standard peak ([15N]Aβ1-40, m/z 4378.4).

2.8. Notch Signaling and Processing Assays. Inhibition of Notch signaling in cultured cells using a mouse-derived truncated Notch1 transgene, mNotch-ΔE [67], has been described in detail previously [59]. Western blots for mNotchΔA1865 and NICD using 9E10 anti-c-myc monoclonal were carried out as previously described [68].

2.9. Animals and Dosing. All experimental procedures with animals followed National Institutes of Health guidelines and were authorized by and in compliance with policies of the Bristol-Myers Squibb Animal Use and Care Committee. Mice and rats were housed with a 6:00 AM to 6:00 PM light/dark cycle and allowed free access to food and water. For 3xTg mice [63], BMS-869780 was dosed in three-month-old females by oral gavage at 6 mL/kg in vehicle consisting of 84% polyethylene glycol average molecular weight of 400 (PEG-400), 15% EtOH, and 1% Tween-80 (w/w/w). The compound was dissolved in EtOH and then diluted with PEG-400 and Tween, after which the vial was sealed, vortexed, and sonicated at 56°C for 1 hour. Animals were euthanized by asphyxiation in CO2. Blood was collected by cardiac puncture and placed into ethylene-diaminetetraacetic acid microtainer tubes for the preparation of plasma. The cerebellum was collected for the determination of compound concentration, and the remaining brain was separated into left and right halves before freezing in liquid nitrogen. For the rat time course study, 8- to 12-week-old female Sprague-Dawley rats were obtained from Charles River Laboratories (Wilmington, MA), BMS-869780 was dosed orally at 4 mL/kg, and brain and plasma samples were collected as described for the 3xTg mice. For the four day repeat dose rat study, BMS-869780 was given by oral gavage in vehicle consisting of PEG-400, PEG-200, Dα-tocopheryl polyethylene glycol succinate, Solutol HS 15, in the ratio 80:10:5:5 (w/w/w/w). Methods for the pharmacokinetics studies in rat, dog, and monkey are described below.

2.10. Pharmacokinetic to Pharmacodynamic (PK/PD) Relationship in Rodents. The data generated in the mouse and rat time course experiments were analyzed sequentially by nonlinear regression (WinNonlin Pharsight Corporation, Mountain View, CA). The pharmacokinetic data were best described by a 1-compartment linear model with first-order absorption and elimination. Subsequently, the pharmacodynamic parameters were estimated from the BMS-869780 plasma concentrations and the observed reductions of brain Aβ1-42 or Aβ1-40 by fitting to the equation for inhibition of synthesis [69]. The goodness-of-fit was determined by visual inspection, Akaike Information Criterion, Schwartz Criterion, examination of the residuals and the coefficient of variation of the parameter estimates.
2.11. Pharmacokinetics. Male Sprague-Dawley (SD) rats (300–350g) were fasted overnight, and three per group received BMS-869780 either as an intravenous (IV) infusion in PEG400: ethanol (90:10 w/w) at 1 mg/kg over 5 min via the jugular vein or as nanosuspension (d_{50} ca. 300 nm) by oral gavage at 5 mg/kg in Povidone K-30: sodium laurel sulfate: water (2.5:0.12:97.38 w/w/w). For the IV infusion, serial blood samples were obtained before dose and at 0.17, 0.25, 0.5, 0.75, 1, 2, 4, 6, 8, and 24 hours after dose. For the PO nanosuspension, serial blood samples were obtained before dose and at 0.25, 0.5, 0.75, 1, 2, 4, 6, 8, and 24 hours after dose. Blood samples, ~0.3 mL, for all studies were collected from the jugular vein into K_2 EDTA-containing tubes and then centrifuged at 4°C (1500–2000 × g) to obtain plasma, which was stored at −20°C until analysis by LC/MS/MS. In male beagle dogs, the PK of BMS-869780 was evaluated in a cross-over study design with a one-week washout between treatments. Dogs were fasted overnight, and three animals (9.5 to 10.7 kg) received BMS-869780 by IV infusion at 1 mg/kg over 5 minutes in PEG400: ethanol (90:10 w/w) or as nanosuspension (d_{50} ca. 300 nm) by oral gavage at 5 mg/kg in Povidone K-30: sodium laurel sulfate: water (2.5:0.12:97.38 w/w/w). Serial blood samples (~0.3 mL) were collected from a saphenous vein into K_2 EDTA-containing tubes before dose and at 0.083, 0.17, 0.25, 0.5, 0.75, 1, 2, 4, 6, 8, and 24 hours after IV dose, and 0.25, 0.5, 0.75, 1, 2, 4, 6, 8, and 24 hours after oral dose, followed by centrifugation at 4°C (1500 to 2000 × g) to obtain plasma. Samples were stored at −20°C until analysis of BMS-869780 levels by LC/MS/MS. In male cynomolgus monkeys, the PK of BMS-869780 was evaluated in a cross-over study design with a 1-week washout between treatments. Following an overnight fast, three animals (4.5 to 8 kg) received BMS-869780 by IV infusion via a femoral vein at 1 mg/kg over 10 minutes in PEG400: ethanol (90:10), or by oral gavage at 5 mg/kg in Povidone K-30: sodium laurel sulfate: water (2.5:0.12:97.38). Serial blood samples, ~0.3 mL, were collected from a femoral artery into K_2 EDTA-containing tubes before dose and at 0.083, 0.17, 0.25, 0.5, 0.75, 1, 2, 4, 6, 8, and 24 hours after IV dose, and 0.25, 0.5, 0.75, 1, 2, 4, 6, 8, and 24 hours after oral dose, followed by centrifugation at 4°C (1500 to 2000 × g) to obtain plasma. Samples were stored at −20°C until analysis of BMS-869780 levels by LC/MS/MS. The PK parameters of BMS-869780 were obtained by noncompartmental analysis of plasma concentration versus time data (WinNonlin software, Version 5.0; Pharsight Corporation, Mountain View, CA). The peak concentration (C_{max}) and time for C_{max} (T_{max}) were recorded directly from experimental observations. The area under the curve from time zero to the last sampling time (AUC_{0−T}) and the area under the curve from time zero to infinity (AUC_{INF}) were calculated using a combination of linear and log trapezoidal summations. The total plasma clearance (CL/T), steady-state volume of distribution (Vss), apparent elimination half-life (T_{1/2}), and mean residence time (MRT) were estimated after IV administration. The absolute oral bioavailability (F) was estimated as the ratio of dose-normalized AUC values following oral and IV doses.

2.12. Prediction of Human Dose. Interspecies allometric scaling adjusted for brain weight was used to predict human CL/T [70], while simple allometric scaling was used to predict Vss [71]. Briefly, the Vss and brain weight adjusted CL/T values from nonclinical species were plotted against body weight on a log-log scale to yield estimates of Vss and CL/T × brain weight in humans. The estimated CL/T × brain weight for human was adjusted for the brain weight of humans to yield a predicted CL/T. All of the nonclinical species demonstrated mono- or biexponential plasma concentration-time profiles; therefore, the MRT method was used to simulate the human pharmacokinetic profile as described below. Noncompartmental analysis was performed using WinNonlin software (version 5.0; Pharsight Corporation, Mountain View, CA). The k_{e} for each species was obtained from the IV and PO (nanosuspensions) of rat, dog, and cynomolgus monkey by deconvolution of plasma concentration-time data using Kinetta (version 5.0; Seattle, WA). The bioavailability was estimated from the nanosuspensions from rat, dog, and cynomolgus monkeys. The average k_{e} and F, along with the Vss and CL/T from allometric scaling, were incorporated into a two-compartment model to predict the human oral plasma concentration-time profiles. Human steady state doses to achieve plasma AUCs comparable to those in rats which produced 25% ABEC (area between baseline and Aβ effect-time curve) reductions were estimated. The results are summarized in Tables 3 and 4.

2.13. Determination of BMS-869780 Concentrations. Plasma and brain samples were analyzed using an ultraperformance liquid chromatography-tandem mass spectrometry (UPLC-MS-MS) method. The UPLC MS-MS system consisted of a Waters Acquity Ultra Performance LC Sample Organizer, Solvent Manager and Sample Manager, a Waters BEH C18, 1.7 µm × 50 × 2.1 mm, column operated at 60°C, and a SCIEX API 4000 Q trap mass spectrometer. The mobile phase consisted of (A) water with 0.1% formic acid and (B) acetonitrile with 0.1% formic acid, delivered at 600 µL/min using a gradient program. The initial elution condition was 5% B which was maintained for 0.2 min and increased to 95% B in 0.5 min and maintained for 0.4 min. It was then returned to 5% B in 0.1 min and maintained for 0.2 min. The MS-MS analysis was performed using the heated nebulizer under positive ion mode with the source temperature at 400°C. The capillary voltage was 5000 eV and the collision energy 49 eV. The mass-to-charge ratios of 453 (precursor ion) and 438 (product ion) were used for multiple reaction mode monitoring of BMS-869780. The quantitation range for BMS-869780 was 1 to 5000 nM. Plasma samples were deproteinized and extracted with four portions of acetonitrile. Brain samples (0.1 g) were homogenized in 0.4 mL of acetonitrile.

2.14. Other Methods. Determination of IC_{50} values for inhibition of secreted alkaline phosphatase (SEAP) was carried out using an H4 cell line stably expressing SEAP. Cells were treated overnight with compounds in 384-well format, and SEAP accumulation in the culture media was quantified using a chemiluminescence substrate. The pregnant-X-receptor...
transactivation assay (PXR-TA) was based on the methods of Goodwin et al. [72] as described previously [59]. In the 4-day rat study with BMS-869780, tissues were fixed in 10% neutral buffered formalin, embedded in paraffin, sectioned, stained with hematoxylin and eosin, and examined by light microscopy.

3. Results

3.1. Identification of BMS-869780. The first compounds reported to have GSM activity were NSAIDs that exhibited selective inhibition of Aβ1-42 production [28]. A high throughput screen (HTS) was therefore carried out using FRET-based immunoassays for Aβ1-42 and Aβ1-40 levels in H4-APPsw cultures. Approximately 10^6 compound samples were incubated for 24 hours in H4-APPsw cell cultures, one compound per well in 384-well format, at a single concentration of 13 μM. The 22,304 samples exhibiting greater than 50% inhibition of Aβ1-42 were subsequently restested in triplicate, that is, three additional wells at 13 μM. This yielded 10,010 samples for which the average inhibition of Aβ1-42 in the four test wells was greater than 50%. After elimination of some samples due to previously known Aβ inhibition or chemical reactivity, 8,013 compounds were organized into clusters of related structures based on structural similarities [73], and 2,013 representative compounds were chosen for further evaluation. To rule out nonspecific effects on production or secretion of Aβ, dose response curves were determined for secreted alkaline phosphatase (SEAP) and for Aβ1-42 to compare the IC50 values. This yielded 409 samples that were relatively selective for Aβ1-42 (using a cutoff of ≥5-fold SEAP/Aβ1-42 IC50 ratio). To assess possible selectivity for Aβ1-42 lowering, IC50 values were determined in parallel for Aβ1-42 and Aβ1-40 in ca. 400 samples, and a series of compounds was identified from which BMS-869780 was subsequently derived through iterative improvements in potency and off-target profiles [54, 55]. An outline of the screening tiers and results obtained is shown in Figure 1(b), and the principle of the Aβ assays is shown in Figures 1(c) and 1(d).

3.2. Potency of BMS-869780 and Related Compounds for Aβ1-42 and Aβ1-40-Lowering. While many of the ca. 400 samples showed wide separations between the Aβ1-42 and Aβ1-40 IC50 values, BMS-869780 itself showed only a fourfold separation between the IC50 values (Figure 2(a)), presenting a minimal contrast with GSIs such as BMS-299897 (Figure 2(b)) and BMS-433796 (see summary of IC50 values in Table I). Nevertheless, as a group, compounds chemically related to BMS-869780 showed limited overlap with GSIs based on the separation of Aβ1-42 and Aβ1-40 IC50 values, as illustrated for 236 GSMS and 688 GSIs (Figure 2(c)). This implies different Aβ-lowering mechanisms between the two groups. The ratios between Aβ1-42 and Aβ1-40 IC50 values in the GSM group ranged from little more than two-fold to almost 250-fold, with a trend toward lower ratios for compounds with lower IC50 values (Figure 2(d)). Anticipating subsequent experiments in the 3xTg mouse, the effect of the presenilin M146V FAD mutant on BMS-869780 potency was evaluated. MEF cell cultures lacking endogenous presenilins were therefore cotransfected with human APP-CTFβ and human presenilin, either wild type or M146V allele. The IC50 for Aβ1-42 was ca. 3-fold higher in cultures expressing the M146V allele, relative to cells expressing wild type presenilin. Likewise, Aβ1-40 IC50 values were ca. 3-fold shifted, although the IC50 appeared lower for Aβ1-40 in the wild type MEF cell cultures than in the H4-APPsw cultures. Thus, BMS-869780 appeared to be a little less potent in the context of the presenilin-1 M146V allele. IC50 values are summarized in Table I.

3.3. Evidence for the Noninhibitory Mechanism of BMS-869780 In Vitro. BMS-869780 showed only a 4-fold shift in IC50 values between Aβ1-42 and Aβ1-40. The effect of BMS-869780 on Aβ1-37 and Aβ1-38 was therefore evaluated, as a more diagnostic test of the GSM mechanism [25]. H4-APPsw cultures were treated overnight with BMS-869780, and Aβ peptides were evaluated by mass spectrometry and western blotting. Using MALDI mass spectrometry, Aβ1-37, Aβ1-38, and Aβ1-40 were readily detected in vehicle-treated cultures, although Aβ1-42 levels were near the limit of quantitation. After treatment with BMS-869780 (100 nM), Aβ1-37 and Aβ1-38 were dramatically increased, whereas Aβ1-40 and Aβ1-42 were essentially undetectable (Figure 3(a)). The same conclusion was reached in experiments using a western blot method that separates different forms of Aβ. Increased levels of the shorter Aβ1-37 and Aβ1-38 peptides, which migrate more slowly than Aβ1-40 or Aβ1-42 by this method, were observed in cultures treated with BMS-869780 at 100 nM and 10 nM (Figure 3(b), lanes 3 and 4, resp.). Thus, taking the experimental data illustrated in Figures 2 and 3 together, BMS-869780 increased Aβ1-37 and Aβ1-38, while decreasing Aβ1-40 and Aβ1-42. This suggested that BMS-869780 would have a minimal effect, if any, on APP-CTFα and APP-CTFβ turnover. H4-APPsw cell cultures were therefore treated at high concentrations, relative to the IC50s, of BMS-869780 and the GSI BMS-299897. For APP-CTFα, BMS-299897 caused an 8-fold increase in APP-CTFα, whereas BMS-869780 showed a 1.4-fold increase, averaged across doses (Figure 4(a)). The two compounds also showed a dramatic contrast in their effects on Aβ under these conditions. Whereas the GSI BMS-299897 dramatically reduced all Aβ-x peptides, including Aβ1-42 and Aβ1-40, BMS-869780 selectively lowered Aβ1-42 and Aβ1-40, without any decrease in the overall levels of Aβ1-x (Figure 4(b)). In contrast to the result for APP-CTFα, APP-CTFβ levels were not affected in this experiment by either compound (Figure 4(a)), suggesting that γ-secretase was not a major pathway for APP-CTFβ turnover under these conditions. Indeed, it was recently reported that APP-CTFβ turnover in H4 cells occurs largely through proteasomal and lysosomal pathways, in contrast to APP-CTFα turnover which is more dependent on γ-secretase [74]. Thus, the effect of BMS-869780 on APP-CTFβ could not be directly evaluated in the H4-APPsw cell line under these conditions. To address the effect of BMS-869780 on APP-CTFβ, experiments were carried out in the context of the intended target organ, that
Table 1: Aβ and Notch IC₅₀ values.

<table>
<thead>
<tr>
<th>Assay (cell line)</th>
<th>BMS-869780 (GSM)</th>
<th>BMS-299897 (GSI)</th>
<th>BMS-433796 (GSI)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>IC₅₀ (nM)</td>
<td>sd</td>
<td>n</td>
</tr>
<tr>
<td>Aβ₁-42 (H4-APPsw)</td>
<td>5.1</td>
<td>2.2</td>
<td>13</td>
</tr>
<tr>
<td>Aβ₁-40 (H4-APPsw)</td>
<td>24.1</td>
<td>7.7</td>
<td>7</td>
</tr>
<tr>
<td>Aβ₁-42 (MEF PS1wt)</td>
<td>7.7</td>
<td>2.3</td>
<td>2</td>
</tr>
<tr>
<td>Aβ₁-40 (MEF PS1wt)</td>
<td>11</td>
<td>4</td>
<td>2</td>
</tr>
<tr>
<td>Aβ₁-42 (MEF M146V)</td>
<td>22</td>
<td>1.4</td>
<td>2</td>
</tr>
<tr>
<td>Aβ₁-40 (MEF M146V)</td>
<td>34</td>
<td>9</td>
<td>2</td>
</tr>
<tr>
<td>mNotch1ΔE (luciferase)</td>
<td>&gt;10000</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>mNotch1ΔE/Aβ₁-42</td>
<td>&gt;1785x</td>
<td>723x</td>
<td></td>
</tr>
</tbody>
</table>

Figure 3: BMS-869780 increased the levels of the shorter peptides Aβ₁-38 and Aβ₁-37. (a) Top panel: an equimolar mix of synthetic peptides Aβ₁-37, Aβ₁-38, Aβ₁-39, Aβ₁-40, [¹⁵N]-Aβ₁-40, and Aβ₁-42 was evaluated by MALDI-TOF mass spectrometry. H4-APPsw cell cultures were treated with vehicle (0.1% DMSO—middle panel) or BMS-869780 (100 nM—bottom panel), [¹⁵N]-Aβ₁-40 was added, and Aβ peptides were immunoprecipitated and evaluated by MALDI-TOF mass spectrometry. (b) H4-APPsw cell cultures were treated with BMS-869780 or DMSO vehicle. Aβ peptides were separated by gel electrophoresis in the presence of urea and detected by western blotting. Under these conditions, higher molecular weight Aβ peptides exhibit greater gel mobility. Lane 1: an equimolar mix of synthetic peptides Aβ₁-38, Aβ₁-40, and Aβ₁-42. Lane 2: DMSO vehicle-treated cell culture. Lanes 3–6: Cell cultures treated with BMS-869780 at final concentrations of 100, 10, 1 and 0.1 nM, respectively.
is, in the brain of rats given oral doses of BMS-869780. The GSI BMS-698861 was dosed for comparison. BMS-869780 decreased $\alpha$-B1-40 and $\alpha$-B1-42 and increased $\alpha$-B1-37 and $\alpha$-B1-38 in rat brain. The sum total of $\alpha$-B1-40, $\alpha$-B1-42, $\alpha$-B1-38, and $\alpha$-B1-37 suggested no significant change in overall $\alpha$-B levels (Figure 5(a)). This was consistent with results obtained in the $\alpha$-B1-x assay, which showed no significant decrease despite the robust decrease in $\alpha$-B1-42 (Figure 5(b)). In contrast, BMS-698861 decreased levels of all the peptides, $\alpha$-B1-40, $\alpha$-B1-42, $\alpha$-B1-38, $\alpha$-B1-37, and $\alpha$-B1-x (Figures 5(a) and 5(b)). APP-CTF$\beta$ and APP-CTFx in samples of the same rat brains were evaluated by immunoprecipitation and western blotting. Neither APP-CTF$\beta$ nor APP-CTFx levels were affected in rats given BMS-869780, whereas levels of both peptides increased several-fold in rats given the GSI BMS-698861 (Figures 5(c)–5(f)). Thus, in brain, inhibition of $\gamma$-secretase by BMS-698861 resulted in APP-CTF$\beta$ and APP-CTFx accumulation, whereas modulation of $\alpha$-B by BMS-869780 had no effect on APP-CTF$\beta$ or APP-CTFx levels.

3.4. BMS-869780 Does Not Inhibit Notch Processing. The effect of BMS-869780 on Notch processing was evaluated using transcriptional reporter assays and western blotting of NICD levels. HeLa cell cultures were transfected with mNotch$\Delta$E and CBFI-luciferase reporter constructs and treated with BMS-869780. In most replicates of this experiment, inhibition of luciferase reporter occurred with IC$_{50}$ > 10 $\mu$M. In contrast, the GSIs BMS-299897 and BMS-433796 robustly inhibited luciferase activation, with IC$_{50}$ = 340 nM and 2.1 nM, respectively (Figure 6(a)). The IC$_{50}$ values for Notch-dependent luciferase expression are summarized in Table 1. To further evaluate the effect of BMS-869780 on Notch processing, western blots of cell cultures were carried out using mNotch$\Delta$1865, a truncated version of mNotch$\Delta$E that facilitates separation of NICD product from mNotch1 substrate on western blots [68]. HeLa cell cultures were transfected with mNotch$\Delta$1865 and treated overnight with compounds before western blotting. BMS-869780 had no effect on NICD levels at concentrations up to 3 $\mu$M, whereas the GSIs, BMS-299897, and BMS-433796, greatly reduced NICD (Figure 6(b)). Furthermore, the GSIs caused an increased level of mNotch$\Delta$1865 substrate, most likely due to inhibition of its turnover by $\gamma$-secretase, as previously noted by Blat et al. [68]. In contrast, 10 $\mu$M BMS-869780 did not increase mNotch$\Delta$1865 levels (Figure 6(b)), suggesting that the concomitant loss of NICD at 10 $\mu$M was due to a nonspecific effect, rather than inhibition of mNotch$\Delta$1865 turnover. This was also consistent with the observation of detached and dead cells in the presence of 10 $\mu$M BMS-869780.

3.5. Evaluation of BMS-869780 PK/PD and Residual Levels of $\alpha$-B. To evaluate BMS-869780 PK/PD, rats were given BMS-869780 intraperitoneally at a range of doses from 0.3 mg/kg to 100 mg/kg. The GSI BMS-698861 was dosed at 30 mg/kg for comparison. Five hours after dosing, brain $\alpha$-B1-42 and brain $\alpha$-B1-40 exhibited dose-dependent lowering with ca. 50% lowering at 3 mg/kg, and plasma $\alpha$-B1-40 lowering was dose dependent with ca. 50% lowering at 0.3 mg/kg (Figure 7(a)). In contrast, brain $\beta$-B1-x levels were not affected by BMS-869780 ($\beta$-B1-x was evaluated only in samples from the highest three doses). For comparison, the GSI, BMS-698861, caused robust lowering in all $\beta$-B assays, including $\beta$-B1-x (Figure 7(a)). The concentration of BMS-869780 in plasma associated with 50% lowering of brain $\alpha$-B1-40 was ca. 1 $\mu$M (Figure 7(c)). $\alpha$-B1-42 appeared to be less completely inhibited than $\alpha$-B1-40. The linear correlation of $\alpha$-B1-42 with $\alpha$-B1-40 showed an intercept of 19.4% on the $\alpha$-B1-42 axis (Figure 7(b)), indicating a higher assay signal for $\alpha$-B1-42 relative to $\alpha$-B1-40 under conditions of maximal inhibition. Furthermore, at high plasma concentrations of BMS-869780, the best fit curve suggested a residual 29% $\alpha$-B1-42 and 11% $\alpha$-B1-40 assay signal remaining (Figure 7(c)). To investigate the residual assay signal further, brain $\alpha$-B1-42 and brain $\beta$-B1-40 were evaluated in rats given four daily doses of BMS-869780 to achieve high sustained exposures, and residual levels of brain $\alpha$-B1-42 and $\beta$-B1-40 were evaluated by immunodepletion. Despite the high exposures achieved (Table 4) and the extended time period in this experiment, residual ELISA signals for $\alpha$-B1-42 of 31% and for $\beta$-B1-40 of 19% were observed (Figures 7(d) and 7(e)). Immunodepletion of the samples prior to ELISA was carried out to determine how much of the assay signal was due to residual $\alpha$-B1-42 or $\beta$-B1-40. Specific monoclonals 565 and TSD selectively depleted $\alpha$-B1-42 and $\beta$-B1-40, respectively, whereas monoclonal 4G8, which binds both, depleted both $\alpha$-B1-42 and $\beta$-B1-40. The monoclonal 6E10, which selectively binds human $\beta$-B relative to rat $\beta$-B, depleted neither $\alpha$-B1-42 nor $\beta$-B1-40. After immunodepletion, there was a residual signal of 16% for $\alpha$-B1-42 and 4% for $\beta$-B1-40, averaged across depleted samples in both dose groups (Figures 7(d) and 7(e)). Thus, the residual signal appeared to be a combination of nonspecific background signal and small residual pools of ca. 15% $\alpha$-B1-42 and 7% $\beta$-B1-40. This residual $\alpha$-B1-42 may represent either a slow turnover pool of $\alpha$-B1-42 or a source of $\alpha$-B1-42 production that is not readily inhibited by $\gamma$-secretase-targeted compounds.

To evaluate the pharmacokinetic to pharmacodynamic (PK/PD) relationship for BMS-869780 in more detail, time courses of $\alpha$-B lowering and plasma BMS-869780 concentration were carried out in mice and rats. The PK and PK/PD were then modeled sequentially using 1-compartment PK and indirect response PK/PD models, respectively. Triple transgenic mice [63] were dosed orally at 30 mg/kg or 100 mg/kg, and brain and plasma were taken from groups of animals after 3, 5, 8, 16, and 24 hours. Rats were dosed orally at 10 mg/kg, and brain and plasma were taken at the same time points as for mice. Plasma BMS-869780 showed increasing concentration until 4–8 hours then decreased (Figure 8(a)). Brain $\alpha$-B1-42 in the mouse, and both $\alpha$-B1-42 and $\beta$-B1-40 in the rat, decreased until 8–16 hours relative to vehicle-treated groups (Figures 8(b)–8(d)). The in vivo plasma IC$_{50}$ values for brain $\alpha$-B1-42 were 1.9 $\mu$M and 4.0 $\mu$M for rat and mouse, respectively. After taking account of the protein bound fractions (99.5% and 99.6% in rat and mouse, resp.), these are within 2-fold factors of the in vitro IC$_{50}$ values of 5.1 nM and 22 nM for wild type and presenilin-1 M146V alleles, respectively (Table 1). Estimates of the PK and PD parameters are summarized in Table 2. Using the PK
and PK/PD models for the rat data, steady-state assuming linear PK was predicted to occur after three daily doses, and a 3 mg/kg oral dose of BMS-869780 was predicted to yield $AUC_{\text{max}}^{24\text{h}} = 18.6 \mu M\cdot h$ with corresponding $A\beta1-42$ ABEC $\theta_{24\text{h}} = 26.9\%$ at steady state. Observed and predicted values of dose, AUC, and ABEC in rat and mouse are summarized in Table 3.

### 3.6. Pharmacokinetics and Human Dose Prediction

To make a prediction of human PK for BMS-869780, the PK profiles for solution IV and nanoparticle suspension PO dosing of BMS-869780 were determined in rat, dog, and cynomolgus monkey (Figure 9; Table 4). Plasma exposure was readily detectable for 24 hours after dosing, and the average bioavailability of the nanoparticle suspension for the three species was 28%. Allometric scaling of the observed animal PK parameters was used to predict human PK parameters (Table 4) [70, 71]. From the predicted human PK, in combination with the PK/PD parameters from rat, a 10 mg/kg once daily dose (700 mg total) was predicted to achieve a steady-state $AUC = 178 \mu M\cdot h$, $C_{\text{max}} = 1.27 \mu M$, and corresponding brain $A\beta1-42$ ABEC $= 25\%$ (Table 3).

### 3.7. Off-Targets and Safety

BMS-869780 was evaluated in a range of in vitro off-target activity assays. In one of these assays, pregnane-X-receptor transactivation (PXR-TA), BMS-869780 exhibited robust activity. In further experiments, BMS-869780 was shown to increase CYP3A4 mRNA expression in primary human hepatocytes. In both the PXR-TA and the primary human hepatocytes, transcription was activated at concentrations of 0.3 $\mu M$ and above (Figure 10(a)), suggesting potential activation of CYP3A4 metabolism and risk for drug-drug interactions in human at the exposures predicted to lower $A\beta1-42$.

As a preliminary evaluation of safety in vivo, male and female rats were given 10, 30, and 100 mg/kg BMS-869780 orally once daily for 4 days. Endpoints included brain $A\beta1-42$, as described above (Figures 7(d) and 7(e)), plasma PK on day 1 and day 3 (Table 4), and histopathology for duodenum, liver, and kidney. There was no loss of exposure between day 1 and day 3, consistent with a lack of autoinduction via PXR and/or lack of BMS-869780 metabolism by CYP3A in the rat. Duodenum and kidney histology were unchanged at all dose levels. However, liver exhibited macro- and microvesicular vacuolar degeneration consistent with a fatty acid change, likely lipidosis, at all doses (Figures 10(b) and 10(c)). In the 10 mg/kg dose groups, the lowest mean $AUC = 17.5 \mu M\cdot h$, and $C_{\text{max}} = 1.9 \mu M$, were commensurate with the target exposures determined for $A\beta1-42$ lowering (see Table 3). In contrast, even at the highest dose of 100 mg/kg, where exposures in excess of 200 $\mu M\cdot h$ were achieved, there was no Notch-related effect on differentiation in the duodenum.

### 4. Discussion

The discovery and evaluation of BMS-869780 started with a high-throughput screen of the BMS compound inventory to identify selective inhibitors of $A\beta1-42$ in cell cultures and ended with predictions for human dose and exposure margins for off-target activity and safety. BMS-869780 is a GSM that decreased production of the longer peptides, $A\beta1-40$ and $A\beta1-42$, and increased production of the shorter peptides, $A\beta1-37$ and $A\beta1-38$. BMS-869780 did not significantly inhibit overall levels of $A\beta$ production, APP-CTF processing, or Notch processing.

#### 4.1. Potency and Mechanism of BMS-869780

BMS-869780 exhibited high potency ($IC_{50} = 5.6 \text{ nM}$) for $A\beta1-42$ lowering in cell cultures, greater or equal in potency to the most potent...
Figure 5: BMS-869780 modulated Aβ but did not cause accumulation of βCTF or αCTF in rat brain. Rats were given oral doses of BMS-869780, and levels of brain Aβ, βCTF, and αCTF were determined 24 hours later. For comparison, BMS-698861 was dosed in a separate experiment and samples were taken 5 hours later. (a) Brain levels of Aβ1-42 (red), Aβ1-40 (green), Aβ1-38 (blue), and Aβ1-37 (purple) are shown as bars stacked upon one another. The total height of each bar therefore represents the sum of the four peptides. (b) Aβ1-42 (red—left Y axis) and Aβ1-x (grey—right Y axis). The same results for Aβ1-42 are plotted in both (a) and (b). (c) Rat brain βCTF was detected by western blotting of immunoprecipitates from samples of the same rat brains used for Aβ determinations. V, vehicle groups; results from rats dosed with 1.9, 22, 100, and 235 mg/kg of BMS-869780 and 10 mg/kg BMS-698861 (GSI) are indicated. (d) Western blots of immunoprecipitated αCTF from the same rat brain samples. (e) and (f) quantification of western blots shown in (c) and (d), respectively, expressed relative to percent of average level of CTF in vehicle-treated rats. Actual doses of BMS-869780 were determined by analysis of concentrations in left-over dosing solutions.
Figure 6: BMS-869780 did not inhibit Notch cleavage in vitro. (a) HeLa cell cultures were transfected with mNotchΔE and CBF1-luciferase reporter constructs, treated overnight with BMS-869780 (●), BMS-299897 (▲), or BMS-433796 (◆), and luciferase assays were carried out. (b) HeLa cell cultures were transfected with mNotchΔ1865, treated with compounds overnight, and cell extracts were evaluated by western blot using anti-c-myc-HRP conjugate. Lanes 1 and 9: DMSO (0.1%) vehicle. Lane 2: BMS-299897 at 1 μM. Lane 3: BMS-433796 at 0.3 μM. Lanes 4–8: BMS-869780 at 0.1, 0.3, 1, 3, and 10 μM, respectively.

Table 2: PK/PD model values from mouse and rat studies.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Units</th>
<th>Mouse CV (%)</th>
<th>Rat CV (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kel</td>
<td>h⁻¹</td>
<td>0.28</td>
<td>0.10</td>
</tr>
<tr>
<td>V/F</td>
<td>L/kg</td>
<td>1.94</td>
<td>1.94</td>
</tr>
<tr>
<td>Kal (10 mg/kg)</td>
<td>h⁻¹</td>
<td>0.11</td>
<td>0.19</td>
</tr>
<tr>
<td>Kal (30 mg/kg)</td>
<td>h⁻¹</td>
<td>0.046</td>
<td>0.19</td>
</tr>
<tr>
<td>Ka2 (100 mg/kg)</td>
<td>h⁻¹</td>
<td>0.046</td>
<td>30.0</td>
</tr>
<tr>
<td>K_{OUT}</td>
<td>h⁻¹</td>
<td>0.72</td>
<td>0.48</td>
</tr>
<tr>
<td>IC_{50}</td>
<td>nM</td>
<td>3979</td>
<td>1892</td>
</tr>
<tr>
<td>R0</td>
<td>%</td>
<td>100</td>
<td>100</td>
</tr>
<tr>
<td>I_{max}</td>
<td>%/h</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>K_{in}</td>
<td></td>
<td>72</td>
<td>48</td>
</tr>
</tbody>
</table>

Kel-first order rate constant for drug elimination; V-volume of distribution; Ka rate constant for drug absorption; K_{OUT}-first order rate constant for degradation of Aβ1-42 or Aβ1-40; IC_{50}-plasma concentration required for 50% inhibition of Aβ1-42 or Aβ1-40 production; R is the response in Aβ1-42 or Aβ1-40 levels, assumed 100% at time zero, R0; I_{max}-range of the response of Aβ1-42 or Aβ1-40 levels; K_{in}-zero order constant for Aβ1-42 or Aβ1-40 production.

Table 3: Relationship between dose, plasma AUC, and Aβ ABEC.

<table>
<thead>
<tr>
<th>Dose</th>
<th>Plasma AUC^{0–24hr} (μM·h)</th>
<th>Brain Aβ ABEC^{24hr}</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mouse 30 mg/kg PO solution (observed 0–24 hours)</td>
<td>45.9</td>
<td>30.9</td>
</tr>
<tr>
<td>Mouse 100 mg/kg PO solution (observed 0–24 hours)</td>
<td>102</td>
<td>55.1</td>
</tr>
<tr>
<td>Rat 10 mg/kg PO solution (observed 0–24 hours)</td>
<td>46.3</td>
<td>47.0</td>
</tr>
<tr>
<td>Rat 3 mg/kg PO solution (predicted steady state after 3 daily doses)</td>
<td>18.6</td>
<td>26.9</td>
</tr>
<tr>
<td>Human 700 mg PO suspension (predicted steady state)</td>
<td>17.8</td>
<td>25</td>
</tr>
</tbody>
</table>

* Dose predicted to achieve Aβ42 ABEC of ca. 25%.
**Figure 7**: BMS-869780 dose response and evaluation of residual Aβ levels in rat brain. (a) Groups of rats received intraperitoneal (IP) injections of vehicle or BMS-869780 at doses of 100, 30, 10, 3, 1, and 0.3 mg/kg. Additional rats were dosed with GSI BMS-698861 at 30 mg/kg as a positive control for Aβ-lowering. Group sizes were seven rats for each dose of BMS-869780 and 14 rats for vehicle and GSI dose groups. Brain and plasma were harvested 5 hours after dosing. Brain Aβ1-42 (green), brain Aβ1-40 (blue), brain Aβ1-40 (black), and plasma Aβ1-40 (red) were determined. Values are expressed as % relative to vehicle group mean. Whiskers represent standard error. ⊗ Aβ1-x was not determined in the groups dosed at 3, 1, and 0.3 mg/kg. (b) Brain Aβ1-40 was plotted against brain Aβ1-42 for each rat dosed with BMS-869780 (black ▲) and for each rat dosed with vehicle (grey ●). Values are expressed as % relative to vehicle group mean. Whiskers represent standard error. (c) Brain Aβ1-42 (●), brain Aβ1-40 (■), and plasma Aβ1-40 (▲) were plotted against plasma concentration of BMS-869780 and the data were evaluated by fit to a four-parameter dose response curve. The top of the dose response curve was defined by vehicle group mean (100%), and the apparent IC₅₀ values in terms of the plasma BMS-869780 concentration obtained for brain Aβ1-42, brain Aβ1-40, and plasma Aβ1-40 were 807 nM, 943 nM, and 84 nM, respectively. The respective 95% confidence intervals were 618–1053 nM, 704–1264 nM, and 44–158 nM. (d) Rats were dosed once daily with BMS-869780 for 4 days at 10 and 100 mg/kg or vehicle, plasma, and brain samples were taken 5 hours after the last dose, and immunodepletion of the brain extracts was carried out prior to Aβ1-42 ELISA assays. Specific monoclonals used were 565 (Aβ1-42 selective), TSD (Aβ1-40 selective), 4G8 (binds both Aβ1-42 and Aβ1-40), and 6E10 (does not bind rat Aβ). After immunodepletion, Aβ1-42 was assayed by ELISA. (e) Same as described in (d), except that Aβ1-40 ELISA was carried out following the immunodepletion.
GSMs reported [39, 43, 75, 76], and was robustly active in vivo, capable of lowering brain Aβ1-42 and Aβ1-40 in mice and rats by 75% or more. At the same time, levels of Aβ1-37 and Aβ1-38 were increased by BMS-869780, such that overall levels of Aβ remained essentially unchanged. The effect of BMS-869780 on γ-secretase therefore does not appear to involve inhibition. To evaluate the mechanism of BMS-869780 further, APP processing intermediates were evaluated both in H4-APPsw cell cultures and in rat brain. Levels of APP-CTFβ and APP-CTFα were not affected by BMS-869780, in contrast to the GSIs BMS-698861 and BMS-299897, which caused robust accumulation. An unexpected observation emerged in the H4-APPsw cell line when it was found that GSI treatment, while causing robust APP-CTFα accumulation, did not result in APP-CTFβ accumulation. This appears to be a quirk of the H4-APPsw cell line, possibly resulting from APP-CTFβ degradation taking place predominantly through the proteasomal and lysosomal pathways, as recently reported [74]. In rat brain, γ-secretase inhibition caused robust increases in both APP-CTFα and APP-CTFβ. In contrast, while BMS-869780 caused robust decreases in Aβ1-42 and Aβ1-40, there was no effect on APP-CTFα and APP-CTFβ levels in rat brain. Thus, in the target organ, brain, BMS-869780 was demonstrated to act solely as a GSM, without inhibitory effects on γ-secretase.

The in vivo potency of BMS-869780 for brain Aβ1-42 lowering in rat and 3xTg mouse was evaluated in single dose time course experiments using a PK/PD indirect response model. This yielded in vivo IC50 values that were within a factor of 2-fold of the IC50 values for Aβ1-42 determined in vitro, when plasma protein binding was taken into account. In the 3xTg mouse, the in vivo and in vitro IC50 values were also within a factor of 2-fold when the effect of the presenilin-1 M146V allele on potency was additionally taken into account. The potency of BMS-869780 for Aβ1-42 lowering was ca. 3-fold less in cell cultures expressing the presenilin-1 M146V allele, consistent with previous reports that presenilin FAD mutants can affect the potency of GSMs [77, 78]. Thus, the in vivo activity of BMS-869780 in rodents corresponded well with its potency determined in vitro, suggesting that rodents would be predictive of activity in human.

### 4.2. Lack of Notch Inhibition by BMS-869780

The lack of effect of BMS-869780 on Notch processing was demonstrated using three approaches. First, a luciferase transcriptional reporter assay for Notch1 signaling was tested in cell cultures. For BMS-869780, the ratio of Notch to Aβ1-42 IC50 was not precisely determined because of its weak activity in the Notch assays but was >1785-fold, based on an IC50 value >10 μM for Notch. In the same assays, GSIs exhibited a wide range of Notch/Aβ1-42 IC50 ratios, with values of 13 and 723 for BMS-433796 and BMS-299897, respectively (Table 1). For GSIs, it has been shown that the absolute values of Notch/Aβ1-42 IC50 ratios for GSIs are strongly affected by APP substrate expression levels [61], and therefore cell culture data do not translate directly to Notch/Aβ1-42 margins in vivo. For example, the relatively Notch-selective GSI avagacestat exhibited a Notch/Aβ1-40 IC50 ratio of 193 [59], but the doses that achieved Aβ lowering without Notch-related side effects were more limited in vivo [19]. For BMS-869780, the lack of Notch-related side effects is expected based not only on the large in vitro Notch/Aβ1-42 IC50 ratio, but also on its noninhibitory mechanism of γ-secretase modulation. In rats, BMS-869780 did not cause any histological change in duodenum, specifically a lack of goblet cell metaplasia, even after four days of dosing at high exposures. The plasma exposure of BMS-869780 achieved in this experiment was more than 12-fold above the exposure required for lowering Aβ1-42 by 25% (Aβ1-42 ABEC = 25%). A wide variety of evidence from human genetics and transgenic APP mouse models suggests lowering of Aβ1-42 by 25% would be beneficial in AD [7]. Taken together, these data support the idea that GSMs such as BMS-869780 do not cause Notch-related side effects at doses predicted to cause sufficient Aβ1-42 lowering.

### 4.3. Human Predictions for BMS-869780

To predict human dose, off-target, and safety margins, the PK/PD relationship determined in rodents was used as a guide, and a target Aβ1-42 ABEC = 25% was chosen, based on evidence from rodent models that 25% might ultimately translate to a significant effect in AD [7]. The assumption that human

---

**Table 4: Summary pharmacokinetics observed in three species and predicted in human.**

<table>
<thead>
<tr>
<th></th>
<th>Rat</th>
<th>Dog</th>
<th>Monkey</th>
<th>Human predicted</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>IV 1 mg/kg</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clearance (mL/min/kg)</td>
<td>24.3 ± 1.7</td>
<td>5.7 ± 1.7</td>
<td>15.2 ± 5.9</td>
<td>5.6</td>
</tr>
<tr>
<td>AUCLast (nMh)</td>
<td>1484 ± 121</td>
<td>6640 ± 2257</td>
<td>2632 ± 926</td>
<td></td>
</tr>
<tr>
<td>Half-life (hour)</td>
<td>2.0 ± 0.3</td>
<td>5.2 ± 1.4</td>
<td>4.0 ± 0.5</td>
<td>13</td>
</tr>
<tr>
<td>MRT (hour)</td>
<td>1 ± 0.2</td>
<td>6.6 ± 2.0</td>
<td>3.8 ± 0.7</td>
<td></td>
</tr>
<tr>
<td>Vss (L/kg)</td>
<td>1.8 ± 0.5</td>
<td>2.2 ± 0.8</td>
<td>3.7 ± 1.3</td>
<td>5.2</td>
</tr>
<tr>
<td><strong>PO suspension 5 mg/kg</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AUCLast (nMh)</td>
<td>3995 ± 964</td>
<td>4546 ± 2157</td>
<td>2031 ± 1038</td>
<td></td>
</tr>
<tr>
<td>Cmax (nM)</td>
<td>674 ± 227</td>
<td>487 ± 155</td>
<td>219 ± 94</td>
<td></td>
</tr>
<tr>
<td>Tmax (hour)</td>
<td>3.3 ± 1.2</td>
<td>1.7 ± 0.6</td>
<td>2.0 ± 0.0</td>
<td></td>
</tr>
<tr>
<td>F (%)</td>
<td>54%</td>
<td>13%</td>
<td>16%</td>
<td>28%</td>
</tr>
</tbody>
</table>

MRT-mean residence time; AUCLast-area under the plasma concentration-time curve from zero time until the last quantifiable concentration.
Figure 8: Analysis of the PK/PD relationship for BMS-869780 in rats and mice. Rats were dosed orally with BMS-869780 at 10 mg/kg, and triple transgenic mice were orally dosed at 30 mg/kg and 100 mg/kg. Additional groups of rats and mice were dosed with vehicle alone. Brain and plasma were harvested at 3, 5, 8, 16, and 24 hours after dosing for determination of brain Aβ1-42 and plasma BMS-869780 concentration. Group sizes were 5 rats or 4 mice. Whiskers represent standard error. (a) Plasma concentrations of BMS-869780 were determined for the mice dosed at 100 mg/kg (▲) and 30 mg/kg (◼) and for the rats dosed at 10 mg/kg (▼). The data were fit to a one-compartment PK model and the predicted plasma BMS-869780 concentrations are shown for mouse (solid lines) and rat (broken line). (b) Brain Aβ1-42 levels were determined for the mice dosed with BMS-869780 at 100 mg/kg (▲), 30 mg/kg (◼), or vehicle alone (●). The data were fitted using the indirect pharmacodynamic response model and predicted values are shown (solid lines). (c) Brain Aβ1-42 levels were determined for the rats dosed with BMS-869780 at 10 mg/kg (▼) or vehicle alone (●). The data were fitted using the indirect pharmacodynamic response model and predicted values are shown (dashed line). The values of the PK and PD parameters determined from these experiments are summarized in Table 2. (d) Brain Aβ1-40 levels determined in the same rats as illustrated in (c).

and rat PK/PD would be similar was supported by the concordance of the human in vitro IC₅₀ with the in vivo IC₅₀s determined in rat and mouse, as discussed above. The human PK parameters were then predicted through allometric scaling of PK in three species; rat, dog, and monkey, using the average bioavailability (F = 28%) achieved with a nanosuspension. The nanosuspension was chosen as a clinically relevant formulation with potential to enhance bioavailability. A dose of 700 mg was calculated to achieve brain Aβ1-42 ABEC = 25%, with associated AUC = 17.6 μM·h and C_max = 1.27 μM. These AUC and C_max values were then used as benchmarks to compare the Aβ1-42 lowering activity against in vivo side effects and in vitro off-target activities. BMS-869780 did not cause duodenal neoplasia, the characteristic Notch-related side effect observed in rats given GSIs, even after four days dosing that achieved AUC = 316 μM·h and C_max = 15.5 μM (Table 5). This predicted a safety margin, specifically related to duodenal toxicity, including
Notch-related side effects in rat, of at least 12-fold above the Aβ1-42 lowering exposure benchmarks. On the other hand, lipidosis in the liver was observed after four daily doses of 10 mg/kg with mean $C_{\text{max}} = 1.9 \mu M$ and AUC = 17.5 $\mu M$ (Table 5), indicating no separation of hepatotoxicity from the Aβ1-42 lowering exposure benchmarks. Subsequent studies with other potent GSMs (not shown) did not exhibit hepatotoxicity under these conditions, suggesting an off-target mechanism of hepatotoxicity. BMS-869780 was evaluated in a wide range of in vitro off-target activity assays. In the case of the human PXR transcriptional reporter assay, BMS-869780 was found to be active at concentrations of 0.3 $\mu M$ and above. Further experiments confirmed the activation of CYP3A4 transcription in primary human hepatocyte cultures at similar concentrations, raising the possibility of metabolic induction and risk of drug-drug interactions at exposures required for Aβ1-42 lowering in human [79]. An overview of how experimental data were combined to determine off-target and safety margins is shown in Figure 11. In general, many GSMs exhibit poor drug-like properties, in particular high lipophilicity resulting in high active exposures and risk of systemic toxicity. Nevertheless, approaches for further optimization have been proposed, and the potential to improve drug-like properties has been demonstrated [80]. Alternatively, identification of new structural scaffolds might eventually lead to compounds with improved properties. Whether by optimization of current leads or new scaffolds, potentially the most useful guide for future compound design would be the availability of high resolution structures for GSM binding to $\gamma$-secretase.
Figure 10: BMS-869780 caused PXR activation in vitro and lipidosis in rat liver. (a) PXR activation in the presence of BMS-869780 was evaluated in HepG2 cell cultures using a luciferase transcriptional reporter construct (●), or by assay of CYP3A4 mRNA levels in primary human hepatocyte (PHH) cultures from two individual donors (▲ and ▼). Activation in both assays is expressed as % relative to activation in the presence of rifampicin, 10 μM, in parallel cultures. (b) Liver section from vehicle-dosed rats. (c) Liver section from rats given 4 daily doses of BMS-869780 at 100 mg/kg. A summary of the plasma BMS-869780 exposures from this experiment is shown in Table 5.

Table 5: Summary of exposure in rat 4-day dosing experiment.

<table>
<thead>
<tr>
<th>Dose (mg/kg)</th>
<th>Male</th>
<th>Day 1</th>
<th>C_{max} (μM)</th>
<th>Day 1</th>
<th>Day 3</th>
<th>Female</th>
<th>Day 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>10</td>
<td>2.0 (±0.4)</td>
<td>1.9 (±0.46)</td>
<td>2.9 (±0.4)</td>
<td>2.6 (±0.06)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>30</td>
<td>6.1 (±1.8)</td>
<td>10.4 (±2.0)</td>
<td>8.2 (±1.7)</td>
<td>14.4 (±1.0)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>100</td>
<td>7.7 (±0.9)</td>
<td>13.2 (±1.5)</td>
<td>10.6 (±1.0)</td>
<td>15.5 (±2.3)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Dose (mg/kg)</th>
<th>Male</th>
<th>Day 1</th>
<th>AUC (0–24 h) (μM·h)</th>
<th>Day 1</th>
<th>Day 3</th>
<th>Female</th>
<th>Day 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>10</td>
<td>20.2 (±4.8)</td>
<td>17.5 (±5.7)</td>
<td>41.0 (±5.6)</td>
<td>25.0 (±1.5)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>30</td>
<td>95.2 (±19.9)</td>
<td>128.6 (±65.0)</td>
<td>152.2 (±21.0)</td>
<td>255.1 (±28.5)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>100</td>
<td>167.5 (±14.5)</td>
<td>216.9 (±80.5)</td>
<td>205.9 (±43.2)</td>
<td>316.4 (±770)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Dose (mg/kg)</th>
<th>Male</th>
<th>Day 1</th>
<th>T_{max} (h)</th>
<th>Day 1</th>
<th>Day 3</th>
<th>Female</th>
<th>Day 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>10</td>
<td>5.0 (±2.0)</td>
<td>5.0 (±2.0)</td>
<td>7.0 (±2.0)</td>
<td>5.0 (±2.0)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>30</td>
<td>8.0 (±0.0)</td>
<td>3.0 (±1.0)</td>
<td>5.0 (±2.0)</td>
<td>3.0 (±1.0)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>100</td>
<td>19.0 (±9.0)</td>
<td>7.0 (±2.0)</td>
<td>24 (±0.0)</td>
<td>4.0 (±4.0)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Dose (mg/kg)</th>
<th>Male</th>
<th>Terminal concentration day 4 (μM)</th>
<th>Female</th>
</tr>
</thead>
<tbody>
<tr>
<td>10</td>
<td>2.4 (±0.6)</td>
<td>3.0 (±0.3)</td>
<td></td>
</tr>
<tr>
<td>30</td>
<td>8.9 (±1.9)</td>
<td>12.0 (±4.6)</td>
<td></td>
</tr>
<tr>
<td>100</td>
<td>9.2 (±3.2)</td>
<td>13.7 (±0.9)</td>
<td></td>
</tr>
</tbody>
</table>
In conclusion, BMS-869780 demonstrated the potential of the GSM approach, namely, the high potency, the robust translation of activity and mechanism in vitro, and the absence of a Notch-related side effect after multiple days of dosing at high sustained exposures. While liver toxicity and the high predicted dose of 700 mg caused studies of BMS-869780 to be discontinued, there was no evidence to suggest that liver toxicity or PXR activation were intrinsic to the GSM mechanism. In principle, therefore, an optimal combination of sufficient potency, PK, pharmaceutical properties, and off-target profile is within reach for testing a future GSM in Alzheimer's disease.

**Abbreviations**

- **ABEC:** Area between baseline and Aβ effect-time curve
- **AD:** Alzheimer's disease
- **APP:** β-Amyloid precursor protein
- **APP-CTF:** β-Amyloid precursor protein C-terminal fragment
- **AUC:** Area under the plasma concentration-time curve
- **CYP3A4:** Cytochrome P450 3A4 isozyme
- **DMEM:** Dulbecco's modified Eagle's medium
- **ELISA:** Enzyme-linked immunosorbent assay
- **FAD:** Familial Alzheimer's disease
- **FRET:** Förster resonance energy transfer
- **GAPDH:** Glyceraldehyde-3-phosphate dehydrogenase
- **GSM:** γ-Secretase modulator
- **GSI:** γ-Secretase inhibitor
- **HTS:** High-throughput screening
- **KO:** Knockout (gene ablation)
- **dKO:** Double knockout (gene ablation)
- **MEF:** Mouse embryonic fibroblast
- **MRT:** Mean residence time
- **NICD:** Notch intracellular domain
- **PD:** Pharmacodynamics
- **PK:** Pharmacokinetics
- **PK/PD:** Pharmacokinetic/pharmacodynamic relationship
- **PXR-TA:** Pregnane-X-receptor transactivation assay
- **SEAP:** Secreted alkaline phosphatase

**Conflict of Interests**

All the authors are employees or former employees of Bristol-Myers Squibb.

**Acknowledgments**

The authors thank their colleagues at Bristol-Myers Squibb for their assistance: Meredith Ferrante, Lizbeth Gallagher, and Chu Ngo, Lead Discovery; Lynn Balanda, Suki Jayachandra, Jane Palmer, and Barbara Robertson, Cell culture Resource Group; Emily Greenough, Sandra Matson, and Jay Stevenson, Compound Management; Lisa Johnson for database curation; Antara Majumdar, Biostatistics; Kurt Sims, Discovery Toxicology; Sharon Aborn, James Brennen, Corey Cirillo, Heidi Dulac, Zuzanna Haarhof, Laurie Henson, Jinwen Huang, John Light, Tami Orcutt, Jennifer Pizzano, Megan Quitko, and Cammie Symonowicz, Veterinary Sciences.

**References**


[42] I. Hussain, D. C. Harrison, J. Hawkins et al., “TASTPM mice expressing amyloid precursor protein and presenilin-1 mutant transgenes are sensitive to γ-secretase modulation and amyloid-β42 lowering by GSM-10h,” *Neurodegenerative Diseases*, vol. 8, no. 1-2, pp. 15–24, 2011.


[68] Y. Blat, J. E. Meredith, Q. Wang et al., “Mutations at the P1’ position of Notch1 decrease intracellular domain stability rather
than cleavage by γ-secretase,” *Biochemical and Biophysical Research Communications*, vol. 299, no. 4, pp. 569–573, 2002.


